DE3585072D1 - Retroviraler vektor. - Google Patents

Retroviraler vektor.

Info

Publication number
DE3585072D1
DE3585072D1 DE8585401914T DE3585072T DE3585072D1 DE 3585072 D1 DE3585072 D1 DE 3585072D1 DE 8585401914 T DE8585401914 T DE 8585401914T DE 3585072 T DE3585072 T DE 3585072T DE 3585072 D1 DE3585072 D1 DE 3585072D1
Authority
DE
Germany
Prior art keywords
cells
retroviral vector
promoter
gene
ltr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8585401914T
Other languages
English (en)
Inventor
Francois Jacob
Jean-Francois Nicolas
John Rubenstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur de Lille filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of DE3585072D1 publication Critical patent/DE3585072D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
DE8585401914T 1984-10-01 1985-10-01 Retroviraler vektor. Expired - Fee Related DE3585072D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848424757A GB8424757D0 (en) 1984-10-01 1984-10-01 Retroviral vector

Publications (1)

Publication Number Publication Date
DE3585072D1 true DE3585072D1 (de) 1992-02-13

Family

ID=10567514

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585401914T Expired - Fee Related DE3585072D1 (de) 1984-10-01 1985-10-01 Retroviraler vektor.

Country Status (4)

Country Link
EP (1) EP0178220B1 (de)
AT (1) ATE71146T1 (de)
DE (1) DE3585072D1 (de)
GB (1) GB8424757D0 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2690297B2 (ja) * 1985-08-05 1997-12-10 東レ株式会社 有用たん白質の産生方法
JPH0630590B2 (ja) * 1985-08-30 1994-04-27 株式会社ヤクルト本社 複合プラスミドベクタ−
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
DE3636287A1 (de) * 1986-10-24 1988-04-28 Boehringer Mannheim Gmbh Verfahren zur gentechnologischen herstellung von stoffwechselprodukten in eukaryontenzellen
FR2606030B1 (fr) * 1986-10-31 1989-10-20 Pasteur Institut Retrovirus recombinant defectif, son procede de fabrication et ses applications, notamment pour l'etude de l'interaction des retrovirus sauvages avec des lignees cellulaires infectables par celui-ci
WO1988008454A1 (en) * 1987-04-23 1988-11-03 State Of Oregon Acting By And Through The State Bo Process for amplifying expression and transmission of cloned genes in eukaryotic cells
GB8720855D0 (en) * 1987-09-04 1987-10-14 Oxford University Of Chancello Probe
EP0378576B1 (de) * 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduktionsveränderte fibroblasten und ihre anwendung
PT88556B (pt) * 1987-09-28 1992-11-30 Smithkline Biolog Processo de integracao genomica estavel e de expressao de uma sequencia de cadificacao estranha, em leveduras
US6140111A (en) * 1987-12-11 2000-10-31 Whitehead Institute For Biomedical Research Retroviral gene therapy vectors and therapeutic methods based thereon
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
FR2629469B1 (fr) * 1988-03-31 1990-12-21 Pasteur Institut Retrovirus recombinant defectif, son application a l'integration de sequences codantes pour des proteines determinees dans le genome de cultures cellulaires infectables par le retrovirus sauvage correspondant et adns recombinants pour la production de ce retrovirus recombinant
JPH04504950A (ja) * 1988-11-23 1992-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 位置特異的挿入ベクターおよびこれを用いた方法
ATE219519T1 (de) * 1989-01-23 2002-07-15 Chiron Corp Rekombinanttherapien für infektionen und hyperproliferative störungen
ATE199398T1 (de) * 1989-10-24 2001-03-15 Chiron Corp Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
CA2117303C (en) * 1991-11-29 2000-10-17 Sunil Chada Anti-cancer immunotherapeutic vector constructs
GB2269175A (en) * 1992-07-31 1994-02-02 Imperial College Retroviral vectors
FR2704236B1 (fr) * 1993-04-21 1995-06-23 Pasteur Institut Vecteur rétroviral pour la préparation de cellules recombinantes susceptibles d'être implantées in vivo dans un but thérapeutique.
CA2161122A1 (fr) * 1993-04-21 1994-10-27 Philippe Moullier Implant biocompatible pour l'expression et secretion in vivo d'un compose therapeutique
IL113052A0 (en) 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
FR2731710B1 (fr) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
FR2732357B1 (fr) 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
KR20010020342A (ko) 1997-04-28 2001-03-15 자끄 사비나 종양치료용 맥관형성 길항제의 아데노바이러스-매개 종양내 전달방법
US6875606B1 (en) 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
DK1049767T3 (da) 1998-01-08 2005-09-19 Aventis Pharma Inc En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A)
US6743631B1 (en) 1998-03-17 2004-06-01 North Shore University Hospital Research Corporation Use of human serum resistant vector particles and cell lines for human gene therapy
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
US6506889B1 (en) 1998-05-19 2003-01-14 University Technology Corporation Ras suppressor SUR-8 and related compositions and methods
US6441156B1 (en) 1998-12-30 2002-08-27 The United States Of America As Represented By The Department Of Health And Human Services Calcium channel compositions and methods of use thereof
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
US7060442B2 (en) 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
ES2359625T3 (es) 2000-12-28 2011-05-25 Wyeth Llc Proteina protectora recombinante de.
US7582425B2 (en) 2001-09-21 2009-09-01 The Regents Of The University Of Michigan Atlastin
US7108975B2 (en) 2001-09-21 2006-09-19 Regents Of The University Of Michigan Atlastin
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP2316922B1 (de) 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Humaner neutraliserender Anti-IGFR Antikörper
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7432057B2 (en) 2004-01-30 2008-10-07 Michigan State University Genetic test for PSE-susceptible turkeys
ATE551432T1 (de) 2004-06-21 2012-04-15 Univ Leland Stanford Junior Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege
US7604798B2 (en) 2004-07-15 2009-10-20 Northwestern University Methods and compositions for importing nucleic acids into cell nuclei
CA2629299C (en) 2005-11-12 2017-08-22 The Board Of Trustees Of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
SG173414A1 (en) 2006-07-28 2011-08-29 Sanofi Aventis Fr Composition and method for treatment of tumors
PL2829551T3 (pl) 2006-10-19 2018-04-30 Csl Limited Antagonisty przeciwciała o wysokim powinowactwie wobec receptora alfa 1 interleukiny-13
DK2068922T3 (da) 2006-10-19 2012-10-08 Csl Ltd Anti-IL-13Ralfa1-antistoffer samt deres anvendelser
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CN102203122A (zh) 2008-11-05 2011-09-28 惠氏有限责任公司 用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物
CN103189071A (zh) 2010-08-23 2013-07-03 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
US9063123B2 (en) 2011-03-29 2015-06-23 Dynavax Technologies Corporation Transgenic mice expressing human toll-like receptor 8
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
AU2013229063B2 (en) 2012-03-09 2016-10-06 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
CA2940513C (en) 2013-03-11 2023-08-15 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for ocular inflammation
KR102199096B1 (ko) 2013-09-08 2021-01-06 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
US11053291B2 (en) 2014-02-19 2021-07-06 University Of Florida Research Foundation, Incorporated Delivery of Nrf2 as therapy for protection against reactive oxygen species
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
US9920100B2 (en) 2015-06-05 2018-03-20 The Chinese University Of Hong Kong Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2020097261A1 (en) 2018-11-06 2020-05-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New compositions and methods for treating beta-globinopathies
JP2023510195A (ja) 2020-01-03 2023-03-13 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 歯周の健康を促進するために局所投与されるｔｎａｐ
CA3217862A1 (en) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Animal model having homologous recombination of mouse pth1 receptor
IL308337A (en) 2021-05-13 2024-01-01 Us Health Preparations and methods for the treatment of sickle cell disease
WO2023064255A2 (en) 2021-10-15 2023-04-20 The Regents Of The University Of California Diagnosis and treatment of anti-pf4 induced thrombocytopenia
WO2023081167A2 (en) 2021-11-02 2023-05-11 The Regents Of The University Of California P-selectin mutants and modulation of integrin-mediated signaling
WO2023146807A1 (en) 2022-01-25 2023-08-03 The Regents Of The University Of California Vegf mutants and modulation of integrin-mediated signaling
WO2023200897A1 (en) 2022-04-13 2023-10-19 The Regents Of The University Of California Use of viral il-6 in cancer therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000922A1 (en) * 1984-07-30 1986-02-13 The Salk Institute For Biological Studies Retroviral gene transfer vectors

Also Published As

Publication number Publication date
EP0178220A2 (de) 1986-04-16
EP0178220B1 (de) 1992-01-02
EP0178220A3 (en) 1987-08-26
GB8424757D0 (en) 1984-11-07
ATE71146T1 (de) 1992-01-15

Similar Documents

Publication Publication Date Title
ATE71146T1 (de) Retroviraler vektor.
GB9510272D0 (en) Retroviral vectors
Schambach et al. Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors
Knight et al. Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing
EP1164195A3 (de) Adeno-assoziiertes Virus mit invertierten Terminalen 'Repeats' als Promoter
DE69829471D1 (de) Auf lentivirus basierende gentransfer-vektoren
ATE79649T1 (de) Herpes simplex-virus als vektor.
Vile et al. Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter
WO1996037623B1 (en) Retroviral vectors
DK0738327T3 (da) Vært-vektorsystem til anvendelse ved genterapi
CA1341119C (en) Human erythroid-specific transcriptional enhancer
GB8718779D0 (en) Dna sequence & expression vector
AU2768992A (en) Method for genetically modifying bone marrow cells of primates, and useful cells therefor that produce recombinant retroviral vectors
EP0371119A4 (en) Retroviral vector
EP1760154A3 (de) Sequenzen von natürlischen oder synthetischen Retroelementen, die die Insertion von nukleotiden Sequenzen in eukaryotische Zellen erlauben
ES8800985A1 (es) Procedimiento de preparar proteinas.
BAUM et al. Improved retroviral vectors for hematopoietic stem cell protection and in vivo selection
GB2322131A (en) Improved retroviral vectors for gene therapy
ATE323776T1 (de) Retrovirale vektoren zur expression in embryonalen zellen
ATE277191T1 (de) Retrovirale vektoren für die transduktion des beta-globingens, sowie derivaten der beta-ort kontrollierten region des beta-orts
Jonsson et al. Retrovirus-mediated transduction of an engineered intron-containing purine nucleoside phosphorylase gene
DE3877233D1 (de) Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen.
Moore et al. Evaluation of lymphoid-specific enhancer addition or substitution in a basic retrovirus vector
EP0276591A3 (en) Viral vector and recombinant dna coding for the p25 protein of the aids virus
WO1988009809A3 (en) Cell system for expression of recombinant protein without production of virus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee